Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 13, 2017

View Archived Issues

Ionis Pharmaceuticals licenses drug to Dynacure

EMA's CHMP supports expanding Nplate indication

Preclinical evaluation of selective ATM kinase AZD-1390 inhibitor for treatment of glioblastoma

EMA committee recommends expanding approval of Orkambi

Discovery of novel ERK1/2 inhibitors with robust antitumor activity in vivo

CHMP issues positive opinion on Avastin biosimilar ABP-215

Neurimmune, Ono Pharmaceutical to collaborate on antibodies for neurodegenerative diseases

Devonian Health Group begins phase IIa study of Thykamine in atopic dermatitis

Benralizumab obtains positive opinion in E.U.

FDA accepts for review Sunovion's NDA for dasotraline

EMA committee confirms refusal of Fanaptum MAA

CFTR potentiator GLPG-2451 appears safe in first-in-human study

FDA expands approval of Bristol-Myers Squibb's Sprycel

Phase III results reported for ozanimod in relapsing MS

EMA grants PRIME designation to Mereo's BPS-804

Pfizer initiates phase I study of pegfilgrastim biosimilar PF-06881894

Wound healing improved with SNF-472 in hemodialysis patients with calciphylaxis

PharmaMar expects negative feedback for Aplidin MAA from EMA committee

University of Massachusetts divulges rAAV vectors encoding aspartoacylase

Novel Bcl-2-targeting drugs created at BioVentures

Dana-Farber Cancer Institute presents new anti-EGFR proteolysis-targeting chimera compounds

Baruch S. Blumberg Institute identifies novel glucosidase inhibitors

Five Prime, GlaxoSmithKline present novel neighbor of punc e11 polypeptides

Actelion studies ACT-709478 in patients with photosensitive epilepsy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...